NasdaqGS:ARWRBiotechs
Arrowhead Pharmaceuticals (ARWR) Valuation Check After New Plozasiran And ARO-INHBE Clinical Updates
Arrowhead Pharmaceuticals (ARWR) is back in focus after new clinical and regulatory updates around its siRNA platform, including fresh data for plozasiran and ARO-INHBE that were shared at recent European medical meetings.
See our latest analysis for Arrowhead Pharmaceuticals.
Despite the clinical momentum around plozasiran and ARO-INHBE, short term trading has cooled, with the 7 day share price return down 6.2% and the 30 day share price return down 7.6%, even as the 1 year total shareholder...